ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS

Objective: Isatuximab (Isa, anti-CD38 monoclonal antibody) is approved in combination with carfilzomib (K) and dexamethasone (d), for relapsed multiple myeloma (MM) patients (pts) after ≥1 prior therapy. Final progression free survival (PFS) analysis after 2 years showed mPFS of 35.65 mo (Isa-Kd) vs...

Полное описание

Библиографические подробности

Главные авторы:	Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2023-10-01
Серии:	Hematology, Transfusion and Cell Therapy
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2531137923002018
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!